Schmid, P. Et Al. 2022. Phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY , vol.18 , 233-234.

Schmid, P., Sohn, J. H., Jerez Gilarranz, Y., Gonzalez-Cortijo, L., Sonnenblick, A., Sabanathan, D., ... Korbenfeld, E.(2022). Phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY , vol.18, 233-234.

Schmid, Peter Et Al. "Phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49," ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY , vol.18, 233-234, 2022

Schmid, Peter Et Al. "Phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49." ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY , vol.18, pp.233-234, 2022

Schmid, P. Et Al. (2022) . "Phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49." ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY , vol.18, pp.233-234.

@article{article, author={Peter Schmid Et Al. }, title={Phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49}, journal={ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY}, year=2022, pages={233-234} }